Serum CGRP Changes following Ultrasound-Guided Bilateral Greater-Occipital-Nerve Block

Abdelrahman Abbas; Ramez Moustafa; Ali Shalash; Mahmoud Haroun; Randa Amin; Sherien Borham; Ahmed Elsadek; Shahinaz Helmy

doi:10.3390/neurolint14010016

Serum CGRP Changes following Ultrasound-Guided Bilateral Greater-Occipital-Nerve Block

Neurol Int. 2022 Feb 7;14(1):199-206. doi: 10.3390/neurolint14010016.

Authors

Abdelrahman Abbas¹, Ramez Moustafa¹, Ali Shalash¹, Mahmoud Haroun¹, Randa Amin¹, Sherien Borham¹, Ahmed Elsadek¹, Shahinaz Helmy¹

Affiliation

¹ Department of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.

Abstract

Background: Calcitonin-gene-related peptide (CGRP) and CGRP receptors are expressed in trigeminal nerve cells, and treatments targeting CGRP are effective in migraines. For headaches that do not respond to pharmacological treatment, minimally invasive techniques such as greater-occipital-nerve block (GONB) can help relieve the pain and reduce the frequency of headaches. Our study assessed the efficacy of ultrasound-guided greater-occipital-nerve block (USgGONB) in chronic migraines (CM) and its relationship to serum CGRP levels. Methods: Forty chronic migraineurs who underwent bilateral USgGONB using 40 mg triamcinolone and 1 mL lidocaine were recruited and interictal serum CGRP samples were collected immediately before and one month after GONB. The clinical response was evaluated using headache diaries before and one month after USgGONB. The patient response was determined after USgGONB according to the reduction in headache days as a good responder (>50% reduction), poor responder (<50%) or non-responder. Results: Monthly headache days after GONB showed a significant reduction (median, 10 days; range, 8−14.7) compared to before the block (median, 18 days; range, 17−22; p < 0.001). Across all patients, interictal serum CGRP levels after USgGONB were significantly lower than before the block (median, 40 pg/mL (range, 25−60) vs. 145 pg/mL (range, 60−380) (p = 0.001). The pre-treatment interictal CGRP levels showed a significant difference (p = 0.003), as their levels in non-responders (median, 310 pg/mL; interquartile range, 262−350) were significantly higher than those seen in responders, whether poor responders (median, 135 pg/mL; interquartile range, 100−200 pg/mL) or good responders (median, 140 pg/mL; interquartile range, 80−150 pg/mL). Conclusion: the study showed the beneficial effect of USgGONB in chronic migraines that was associated with lowering interictal CGRP levels, implying a potential role for CGRP in the mechanism of action of GONB in CM, and the interictal CGRP level may be used as a predictor for the response to GONB.

Keywords: CGRP; GONB; chronic migraine.